U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 158 results

Status:
US Approved Rx (2024)
First approved in 2007

Class (Stereo):
CHEMICAL (RACEMIC)



Nebivolol is a competitive and highly selective beta-1 receptor antagonist with mild vasodilating properties, possibly due to an interaction with the L-arginine/nitric oxide pathway. In preclinical studies, nebivolol has been shown to induce endothel...
Status:
US Approved Rx (2001)
First approved in 1992

Class (Stereo):
CHEMICAL (RACEMIC)



Sotalol has both beta-adrenoreceptor blocking and cardiac action potential duration prolongation antiarrhythmic properties. Sotalol inhibits response to adrenergic stimuli by competitively blocking β1-adrenergic receptors within the myocardium and β2...
Status:
US Approved Rx (2024)
First approved in 1992

Class (Stereo):
CHEMICAL (RACEMIC)


Conditions:

Bisoprolol is a cardioselective beta1-adrenergic blocking agent. It lower the heart rate and blood pressure and may be used to reduce workload on the heart and hence oxygen demands. This results in a reduction of heart rate, cardiac output, systolic ...
Status:
US Approved Rx (2000)
First approved in 1988

Class (Stereo):
CHEMICAL (RACEMIC)



Carteolol is a nonselective beta-adrenoceptor blocking agent for ophthalmic use. It has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma and intraocular hypertension. It may be u...
Status:
US Approved Rx (2022)
First approved in 1986

Class (Stereo):
CHEMICAL (RACEMIC)



Esmolol (trade name Brevibloc) is a cardioselective beta1 receptor blocker with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Esmolol decreases the ...
Status:
US Approved Rx (1994)
First approved in 1985

Class (Stereo):
CHEMICAL (ABSOLUTE)



Levobunolol is a non-cardioselective beta-adrenoceptor blocking agent, equipotent at both beta1 and beta2 adrenergic receptors. Levobunolol is greater than 60 times more potent than its dextro isomer in its beta-blocking activity, yet equipotent in i...
Status:
US Approved Rx (2009)
First approved in 1985

Class (Stereo):
CHEMICAL (RACEMIC)



Betaxolol or SL 75212, (± )-1-(isopropylamino)-3-(p-(cyclopropylmethoxyethyl-phenoxy)2-propranol, is a potent cardioselective beta1-adrenoceptor antagonist devoid of intrinsic sympathomimetic activity with very weak local anaesthetic properties. Oral...
Status:
US Approved Rx (1995)
First approved in 1984

Class (Stereo):
CHEMICAL (RACEMIC)



Acebutolol is a cardioselective, beta-adrenoreceptor blocking agent, which possesses mild intrinsic sympathomimetic activity (ISA) in its therapeutically effective dose range. Acebutolol is marketed under the trade names Sectral, Prent. Acebutolol is...
Status:
US Approved Rx (2005)
First approved in 1981

Class (Stereo):
CHEMICAL (RACEMIC)



Atenolol is a Beta-1 cardio-selective adreno-receptor blocking agent discovered and developed by ICI in 1976. Atenolol was launched in the market under the trade name Tenormin in 1976, and became the best-selling Beta-blocker in the world in the 1980...
Status:
US Approved Rx (1993)
First approved in 1979

Class (Stereo):
CHEMICAL (EPIMERIC)



Nadolol is a nonselective beta-adrenergic receptor antagonist with a long half-life, and is structurally similar to propranolol. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac...